Use of CYP2D6 genotyping in practice: Tamoxifen dose adjustment

Pharmacogenomics

Volumn 13, Issue 6, 2012, Pages 691-697

  Walko, Christine M ^a,b   McLeod, Howard ^a,b  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

CYP2D6; genotype guided therapy; pharmacogenomics; tamoxifen

Indexed keywords

DEXTROMETHORPHAN; ENDOXIFEN; MESSENGER RNA; TAMOXIFEN;

AREA UNDER THE CURVE; BREAST CANCER; CANCER SURVIVAL; CYP2D6 GENE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; ETHNICITY; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; OVERALL SURVIVAL; PHENOTYPE; POSTMENOPAUSE; PREMENOPAUSE; PROGRESSION FREE SURVIVAL; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GENE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; POLYMORPHISM, GENETIC; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84859956027     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.27     Document Type: Review

References (23)

1. Osborne CK. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339(22), 1609-1618 (1998). (Pubitemid 28536137)
2. Dellapasqua S, Colleoni M, Gelber R et al. Adjuvant endocrine therapy for premenopausal women with early breast cancer. J. Clin. Oncol. 23(8), 1736-1750 (2005). (Pubitemid 46211426)
3. Hoskins JM, Carey LA, McLeod H. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9(8), 576-586 (2009).
4. Murdter TE, Schroth W, Bacchus-Gerybadze L et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentrations in plasma. Clin. Pharmacol. Ther. 89(5), 708-717 (2001).
5. Wu X, Hawse JR, Subramaniam M et al. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor a for degradation in breast cancer cells. Cancer Res. 69(5), 1722-1727 (2009).
6. Desta Z, Ward BA, Soukhova NV et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310(3), 1062-1075 (2010).
7. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendents. Pharmacogenomics 3(2), 229-243 (2003). (Pubitemid 34223859)
8. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97(1), 30-39 (2005).
9. Stearns V, Johnson MD, Rae JM et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl Cancer Inst. 95(23), 1758-1764 (2003). (Pubitemid 38008898)
10. Borges S, Desta Z, Li L et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implications for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80(1), 61-74 (2006). (Pubitemid 43946844)
11. Schroth W, Goetz MP, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13), 1429-1436 (2009).
12. Leyland-Jones B, Regan MM, Bouzyk M et al. Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. Presented at: 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010.
13. Rae JM, Drury S, Hayes DF et al. Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. Presented at: 33rd Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010.
14. Kim C, Tang G, Pogue-Geile KL et al. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen-receptor positive breast cancer. J. Clin. Oncol. 29(31), 4160-4167 (2011).
15. Madlensky L, Nataragjan L, Tchu S et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin. Pharmacol. Ther. 89(5), 718-725 (2011).
16. Irvin WJ, Walko CM, Weck KE et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J. Clin. Oncol. 29(24), 3232-3239 (2011).
17. Kiyotani K, Mushiroda T, Imamura CK et al. Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res. 131(1), 137-45 (2012).
18. Barginear MF, Jaremko M, Peter I et al. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin. Pharmacol. Ther. 90(4), 605-611 (2011).
19. Hertz DL, McLeod HL, Irvin WJ. Tamoxifen and CYP2D6: a contradiction of data. Oncologist (2012) (In Press).
20. de Graan AJ, Teunissen SF, de Vos FY et al. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J. Clin. Oncol. 29(24), 3240-3246 (2011).
21. Burstein HJ, Prestrud AA, Seidenfeld J et al. American Society of Clinical Oncology Clinical Practice Guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28(23), 3784-3796 (2010).
22. Lorizio W, Rugo H, Beattie MS et al. Pharmacogenomic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med. 3(10), 64-76 (2003).
23. Rae JM, Sikora MJ, Henry NL et al. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J. 9(4), 258-264 (2009).